FILING ANALYSIS · WEDNESDAY, NOVEMBER 4
Innoviva, Inc. INVA — 8-K: Results of Operations and Financial Condition
neutral
Innoviva reported Q3 revenue of $106.1 million, with U.S. net product sales increasing 45% year-over-year to $43.3 million, and the company returned capital to shareholders through a share repurchase program, but a decline in the stock price of Armata Pharmaceuticals led to a net loss of $73.9 million.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →